Group One Trading LLC raised its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 168.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,861 shares of the company’s stock after purchasing an additional 28,765 shares during the period. Group One Trading LLC owned approximately 0.10% of ARK Genomic Revolution ETF worth $1,212,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of ARKG. Ascentis Independent Advisors bought a new position in shares of ARK Genomic Revolution ETF during the first quarter valued at $26,000. PNC Financial Services Group Inc. boosted its position in shares of ARK Genomic Revolution ETF by 53.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock valued at $29,000 after buying an additional 378 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in ARK Genomic Revolution ETF by 734.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock worth $31,000 after buying an additional 984 shares in the last quarter. AlphaCore Capital LLC bought a new stake in ARK Genomic Revolution ETF in the 4th quarter worth about $39,000. Finally, Hilton Head Capital Partners LLC increased its holdings in ARK Genomic Revolution ETF by 161.4% in the 1st quarter. Hilton Head Capital Partners LLC now owns 1,537 shares of the company’s stock worth $41,000 after buying an additional 949 shares in the last quarter.
ARK Genomic Revolution ETF Price Performance
Shares of BATS:ARKG opened at $38.85 on Thursday. The business has a 50-day simple moving average of $36.44 and a two-hundred day simple moving average of $31.80. ARK Genomic Revolution ETF has a fifty-two week low of $22.73 and a fifty-two week high of $44.47.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
